Hugh Wight
Chief Tech/Sci/R&D Officer presso ALLENA PHARMACEUTICALS, INC.
Profilo
Hugh Wight is currently the Senior Vice President-Technical Operations at Allena Pharmaceuticals, Inc. He previously worked as the Director-Quality Systems at Alkermes, Inc., Senior Director-Quality at Altus Pharmaceuticals, Inc., Principal at InSite Vision, Inc., Principal at AutoImmune, Inc., and Principal at Aquila Biopharmaceuticals, Inc. From 2010 to 2012, he served as the Vice President-Technical Operations at Alnara Pharmaceuticals, Inc. He also held the position of Vice President-Technical Operations at Alcresta Therapeutics, Inc. Mr. Wight obtained his undergraduate degree from the University of Maine in 1987.
Posizioni attive di Hugh Wight
| Società | Posizione | Inizio |
|---|---|---|
| ALLENA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
Precedenti posizioni note di Hugh Wight
| Società | Posizione | Fine |
|---|---|---|
Alnara Pharmaceuticals, Inc.
 Alnara Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alnara Pharmaceuticals, Inc. develops and commercializes protein therapeutics for the treatment of metabolic diseases. It also develops liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). The company was founded by Christoph H. Westphal, Richard H. Aldrich and Alexy L. Margolin in 2008 and is headquartered in Boston, MA. | Chief Tech/Sci/R&D Officer | 01/04/2012 |
Alcresta Therapeutics, Inc.
 Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA. | Chief Tech/Sci/R&D Officer | - |
Aquila Biopharmaceuticals, Inc.
 Aquila Biopharmaceuticals, Inc. BiotechnologyHealth Technology Aquila Biopharmaceuticals, Inc. developed and manufactured products for the diagnosis, prevention and treatment of infectious diseases. The company was headquartered in Farmingham, MA. | Corporate Officer/Principal | - |
| INSITE VISION INC. | Corporate Officer/Principal | - |
AutoImmune, Inc.
 AutoImmune, Inc. Pharmaceuticals: MajorHealth Technology AutoImmune, Inc. develop products to treat autoimmune and other cell-mediated inflammatory conditions. Its products are based on a biological mechanism known as oral tolerance, which provides tissue specific immunosuppression without toxicity or significant side effects. The company was founded in September 1988 and is headquartered in Pasadena, CA. | Corporate Officer/Principal | - |
Formazione di Hugh Wight
| University of Maine | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ALLENA PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 7 |
|---|---|
Alkermes, Inc.
 Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Health Technology |
InSite Vision, Inc.
 InSite Vision, Inc. Pharmaceuticals: MajorHealth Technology InSite Vision Inc. develops and markets ophthalmic pharmaceutical products that designs to treat a range of common eye problems, including ocular infection, pain and inflammation in ocular surgery, and glaucoma. Its products include AzaSite, Besivance, AzaSite Plus, DexaSite, AzaSite Xtra, and ISV-10 and 303. The company was founded by Merwin Jerry Hansen in 1986 and is headquartered in Alameda, CA. | Health Technology |
AutoImmune, Inc.
AutoImmune, Inc. Pharmaceuticals: MajorHealth Technology AutoImmune, Inc. develop products to treat autoimmune and other cell-mediated inflammatory conditions. Its products are based on a biological mechanism known as oral tolerance, which provides tissue specific immunosuppression without toxicity or significant side effects. The company was founded in September 1988 and is headquartered in Pasadena, CA. | Health Technology |
Aquila Biopharmaceuticals, Inc.
Aquila Biopharmaceuticals, Inc. BiotechnologyHealth Technology Aquila Biopharmaceuticals, Inc. developed and manufactured products for the diagnosis, prevention and treatment of infectious diseases. The company was headquartered in Farmingham, MA. | Health Technology |
Alnara Pharmaceuticals, Inc.
Alnara Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alnara Pharmaceuticals, Inc. develops and commercializes protein therapeutics for the treatment of metabolic diseases. It also develops liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). The company was founded by Christoph H. Westphal, Richard H. Aldrich and Alexy L. Margolin in 2008 and is headquartered in Boston, MA. | Health Technology |
Altus Pharmaceuticals, Inc.
 Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | Health Technology |
Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA. | Health Technology |
- Borsa valori
- Insiders
- Hugh Wight
